Paolo Tarantino: ASCO Post features ATEMPT’s 5 year update

Paolo Tarantino shared on X:

“Thanks to the ASCO Post for featuring our JCO publication of the ATEMPT 5-year update!

With <1% risk of distant recurrence at 5 years and improved quality of life over chemo, adjuvant T-DM1 should be considered as a valid alternative to TH for stage I HER2+ BC.”